Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
about
Subcutaneous or intramuscular methotrexate for rheumatoid arthritisMethotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of AdministrationPoor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study.Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge.Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study).Methotrexate: an old new drug in autoimmune disease.Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexatePrevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study.Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies.
P2860
Q24187565-3A34C875-735D-42E2-AD6D-8097355FCCB9Q26769021-A1C48C1D-2B9C-47EA-83D6-2546DEA9F744Q33898530-2FC3FC67-0CA5-4B78-A49B-5E3274647069Q33921579-759E7169-B880-4B87-B8F1-91855049F1B0Q34945967-4CDAD572-419A-41FE-881A-5785C52AEF99Q35789299-7FBDC51E-F456-4506-B904-98E8BBB515C9Q38253237-508AB0D4-419E-4E68-B620-B7E78635FA52Q38473460-299698DF-5089-4691-A726-F048C9173B35Q38637780-45CBB335-F3E2-4A40-A66D-84079142981CQ38877301-28217A14-AAC5-4E71-B400-7F5531B088BAQ40073352-6016C034-150D-4751-BA89-AF82CA4B2826Q48340351-135AE952-614B-42BD-86B3-160215EBA622Q50224636-268A10FD-FDA5-4393-9416-BE02F0651CAB
P2860
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Methotrexate in rheumatoid art ...... urrent and emerging paradigms.
@ast
Methotrexate in rheumatoid art ...... urrent and emerging paradigms.
@en
type
label
Methotrexate in rheumatoid art ...... urrent and emerging paradigms.
@ast
Methotrexate in rheumatoid art ...... urrent and emerging paradigms.
@en
prefLabel
Methotrexate in rheumatoid art ...... urrent and emerging paradigms.
@ast
Methotrexate in rheumatoid art ...... urrent and emerging paradigms.
@en
P50
P1476
Methotrexate in rheumatoid art ...... Current and emerging paradigms
@en
P2093
Francesco Carubbi
Piero Ruscitti
P304
P356
10.1016/J.CLINTHERA.2014.01.014
P577
2014-03-05T00:00:00Z